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Involvement of LOX-1 in Dendritic
Cell-Mediated Antigen Cross-Presentation
cross-priming is currently a challenge in antitumor im-
munotherapy.
Heat shock proteins (HSP) are molecular chaperones
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Jean-Franc¸ois Gauchat,1 Jean-Franc¸ois Haeuw,1
Jean-Pierre Aubry,1 Kayo Nakamura,2,3
Naoko Kawakami-Honda,2,3 Liliane Goetsch,1 that control the folding and prevent the aggregation of
proteins (Feldman and Frydman, 2000). Previous studiesTatsuya Sawamura,2,3 Jean-Yves Bonnefoy,1
and Pascale Jeannin1,4 have reported that tumor-derived HSP initiate protective
and tumor-specific CTL responses (Tamura et al., 1997).1Centre d’Immunologie Pierre Fabre
5 avenue Napole´on III The cellular and molecular mechanisms involved have
been partially identified: HSP noncovalently complex74160 Saint Julien en Genevois
France tumor Ag-derived peptides (Udono and Srivastava,
1993; Suto and Srivastava, 1995; Blachere et al., 1997)2 Department of Molecular Pathophysiology
Graduate School of Pharmaceutical Sciences and bind to DC and macrophages (Arnold-Schild et al.,
1999; Wassenberg et al., 1999; Todryk et al., 1999) be-Osaka University
Suita, Osaka 565-0871 fore being internalized in a receptor-dependent manner
(Arnold-Schild et al., 1999; Wassenberg et al., 1999;3 National Cardiovascular Center Research Institute
Fujishirodai Singh-Jasuja et al., 2000; Sondermann et al., 2000). HSP
then colocalize with MHC class I molecules in the earlySuita, Osaka 565-8565
Japan and late multivesicular endosomal structures (Arnold-
Schild et al., 1999; Wassenberg et al., 1999; Singh-
Jasuja et al., 2000).
Several studies have focused on the identification ofSummary
HSP binding structures expressed at the surface of APC.
Recently, CD91 (also known as the 2 macroglobulinSome exogenous antigens, such as heat shock pro-
[2M] receptor) has been reported to be a receptor forteins or apoptotic bodies, gain access to the MHC
human Hsp70, Hsp90, and the endoplasmic reticulumclass I processing pathway and initiate CTL re-
chaperone gp96 on macrophages (Binder et al., 2000;sponses, a process called cross-priming. To be effi-
Basu et al., 2001). CD91 is a member of the lipoproteincient in vivo, this process requires endocytosis of the
receptor family expressed on a variety of cells includingantigen by dendritic cells via receptors which remain
macrophages and smooth muscle cells (Herz and Strick-unidentified. Here, we report that scavenger receptors
land, 2001). CD91 is also involved in gp96-mediatedare the main HSP binding structures on human den-
peptide re-presentation by macrophages (Binder et al.,dritic cells and identify LOX-1 as one of these mole-
2000). Although highly expressed on macrophages,cules. A neutralizing anti-LOX-1 mAb inhibits Hsp70
CD91 expression is very low on dendritic cells. We thenbinding to dendritic cells and Hsp70-induced antigen
used Hsp70 as a probe to identify receptors expressedcross-presentation. In vivo, to target LOX-1 with a tu-
on dendritic cells and involved in HSP-mediated antigenmor antigen using an anti-LOX-1 mAb induces anti-
cross-presentation. We show here that scavenger re-tumor immunity. Thus, the scavenger receptor LOX-1
ceptors, and especially LOX-1, are the main HSP bindingis certainly a promising target for cancer immuno-
structures on human dendritic cells and that LOX-1 istherapy.
involved in in vivo antigen cross-priming.
Introduction Results
T cell epitopes derived from exogenous antigens and Existence of HSP Binding Elements on Human
endocytosed by antigen-presenting cells (APC) are Dendritic Cells
mainly loaded into the MHC class II molecules for recog- FACS analysis showed that biotinylated Hsp70 bound
nition by CD4 T cells. In some conditions, APC are able to peripheral blood myeloid DC in a dose-dependent
to present exogenous antigen in the context of the MHC manner, significant at 1 nM (MFI  8  3; mean  sd,
class I molecules to CD8 T cells, a process called n  5) and maximal at the highest concentration tested,
cross-presentation (Yewdell and Bennink, 1999; Heath 500 nM (MFI  95  12) (Figure 1A). No binding of
and Carbone, 2001). It is thought that antigens have to biotinylated tetanus toxoid (TT), used as a negative con-
be taken up via endocytic receptors to be efficiently trol, was detected (Figure 1A). Similar results were ob-
cross-presented in vivo (Arnold-Schild et al., 1999; Was- tained using Alexa488-labeled Hsp70 and TT (MFI 
senberg et al., 1999; Singh-Jasuja et al., 2000; Castellino 85  7 and 3  2, using 200 nM Alexa488-labeled Hsp70
et al., 2000). Among the APC, dendritic cells (DC) are and TT, respectively; mean  sd, n  5). Hsp70 binding
the only ones able to prime naive T cells and to generate to DC was saturable (Figure 1A) and partly competed
cytotoxic responses (Banchereau et al., 2000). Thus, to by unlabeled Hsp70 (Table 1) but not by TT or BSA
identify receptors expressed by DC and involved in Ag either unlabeled (Figure 1A and Table 1, respectively) or
biotinylated (data not shown). Hsc70 bound in a similar
manner to Hsp70 to peripheral blood myeloid DC (MFI4 Correspondence: pascale.jeannin@pierre-fabre.com
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Figure 1. Scavenger Receptors Are Binding Structures for Hsp70
(A) Hsp70 binds to human DC by a mechanism with the characteristics of a saturable receptor system. Purified human peripheral blood
immature DC were incubated for 20 min with 1 to 500 nM biotinylated Hsp70 () or TT () revealed with Alexa488-labeled streptavidin.
Fluorescence was analyzed by FACS. Results are expressed in MFI values as mean  sd, n  5.
(B) Dot plot profile showing the binding of Hsp70 to human PBMC. Purified human PBMC were incubated for 20 min with 200 nM biotinylated
Hsp70 revealed by Alexa488-labeled streptavidin. Fluorescence was analyzed by FACS.
(C) Maleylated BSA inhibits Hsp70 binding to immature DC. Human immature DC were incubated with 2 M mBSA or BSA. After 20 min, 20
nM biotinylated Hsp70 was added and revealed with Alexa488-labeled streptavidin before analysis by FACS. Results are representative of one
out of five experiments. Gray histrogram corresponds to cells incubated with Alexa488-labeled streptavidin.
(D) Inhibition of Hsp70 binding to human macrophages (Mφ) and peripheral blood myeloid DC. Peripheral blood myeloid DC (open labels)
and macrophages (filled labels) were incubated with 4–2500 nM of 2M (circle), mBSA (square), or transferrin (triangle) (used as control
proteins) before incubation with 20 nM biotinylated Hsp70 revealed with Alexa488-labeled streptavidin. Results are expressed in percentage
of inhibition. One representative from five experiments is presented.
Table 1. Inhibition of Biotinylated Hsp70 Binding to Human Macrophages and Immature Dendritic Cells
Molecules Concentration % Inhibition of Hsp 70 Binding
Immature DC Macrophages LOX-1-CHO
Hsp70 4 M 55  10 59  11 85  7
0.1 M 17  9 9  8 nd
Maleylated BSA 2.5 M 80  10 55  9 96  5
0.1 M 61  8 11  6 nd
BSA 2.5 M 4  3 3  2 5  4
Ox-LDL 2.5 M 75  8 45  8 66  8
Ac-LDL 2.5 M 67  10 52  9 52  7
ApoB 2.5 M 45  8 47  8 70  5
Poly [I] 100 g/ml 94  6 91  5 90  5
Poly [A] 100 g/ml 4  2 4  3 6  4
Fucoidan 50 g/ml 86  9 78  7 85  10
-CD14 mAb 50 g/ml 5  2 4  5 6  3
Control mAb 50 g/ml 4  3 5  6 5  4
2M 2.5 M 27  5 65  6 nd
0.1 M 2  3 18  8 nd
Following incubation with the indicated molecules, cells were washed and further incubated with 20 nM biotinylated Hsp70 followed by
Alexa488-labeled streptavidin. Binding of Hsp70 was analyzed by FACS. Results are representative of five separate experiments and expressed
in % of inhibition of binding (mean  sd). nd, not done.
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Table 2. Hsp70 Binds to Human and Mouse APCs
Hsp70 Binding
Origin Cell Type (MFI Values)
Human Monocytes 89  10
Macrophages 125  19
Myeloid DC 90  12
Mature DC 20  7
B lymphocytes 15  4
T lymphocytes 3  4
Mouse DC 65  9
Binding of biotinylated Hsp70 to different human cell types and to
mouse immature DC was analyzed by FACS. Cells were successively
incubated with 200 nM biotinylated Hsp70 and Alexa488-labeled
streptavidin and then analyzed by FACS. Results are expressed in
MFI values (mean  sd, n  5). Human DC are CD11c peripheral
blood myeloid DC (freshly purified or treated for 48 hr with the
maturation factor LPS).
88  10 using 200 nM biotinylated Hsc70; mean  sd,
n  5) (data not shown). These data suggest that Hsp70
binding structures exist on human APCs (Arnold-Schild
et al., 1999; Wassenberg et al., 1999; Singh-Jasuja et al.,
2000; Castellino et al., 2000, Sondermann et al., 2000).
As previously reported (Arnold-Schild et al., 1999),
biotinylated Hsp70 also bound to subpopulations of pe-
ripheral blood mononuclear cells (identified by double-
color FACS analysis as CD14 monocytes and CD19
B cells) (Figure 1B), to purified human monocytes, mac-
rophages (Arnold-Schild et al., 1999; Wassenberg et al.,
1999; Singh-Jasuja et al., 2000; Sondermann et al.,
2000), and, to a lower extent, to B cells and mature DC
but not to T cells (Table 2 and Castellino et al., 2000).
Interestingly, Hsp60 and Hsp90 presented a similar pat-
tern of binding (data not shown).
Although the Hsp70 used contained low levels of en-
dotoxin (0.5 EU/mg as assessed by the limulus
amebocyte lysate assay), we excluded a potential
involvement of residual endotoxin in Hsp70 binding to
APC based on the following observations: (1) heat treat-
ment of Hsp70 (100C for 20 min) totally abolishes its
binding to APC and (2) polymixin B and LPS do not
prevent Hsp70 binding (data not shown). The involve-
ment of CD14 was suspected in HSP-mediated APC
activation (Asea et al., 2000). A neutralizing anti-CD14
Figure 2. Hsp70 Binds to Recombinant LOX-1
mAb (clone MY4) did not modulate Hsp70 binding to
CHO cells were transfected with the pEBS vector containing the
DC or macrophages (Table 1), and Hsp70 did not bind cDNA encoding for the scavenger receptors LOX-1, CD36, SR-A1,
to CD14-transfected cells (Figure 2). These data do not MARCO, and CLA-1 or CD14. The expression of the SR was evalu-
support a role for CD14 as an Hsp70 receptor. Previous ated either by Western blotting (using an anti-tag protein C mAb as
detection Ab) for SR-A1 and CLA-1 or by FACS for LOX-1, CD36,studies reported that CD91 is a ligand for Hsp70, Hsp90,
and MARCO (using 23C11, anti-CD36 mAb, or an anti-tag proteingp96, and calreticulin on macrophages (Binder et al.,
C mAb, respectively—bound mAbs were detected with Alexa488-2000; Basu et al., 2001). Although Hsp70 bound to hu-
labeled anti-mouse Ig [left panel]). CD14 expression was verified
man macrophages and peripheral blood myeloid DC using Alexa488-labeled anti-CD14 mAb. Binding of fluorescent DiI-
(Table 2), CD91 was detected by FACS on macrophages Ac-LDL (middle panel) and biotinylated Hsp70 (100 nM) detected
but not on DC (MFI  37  5 and 5  4, respectively; with Alexa488-labeled streptavidin (right panel) was evaluated by
FACS. Gray histrograms correspond to unlabeled transfected cells.mean sd, n 5) (data not shown). Together, these data
show that HSP binding elements exist on human immature
DC and suggest that they could differ from CD91. mBSA but not BSA prevented Hsp70 binding to periph-
eral blood myeloid DC (Figure 1C), and, to a lower extent,
to macrophages (80  10% and 55  9% inhibition,Involvement of Scavenger Receptors in Hsp70
Binding to Dendritic Cells respectively; mean  sd, n  5) (Figure 1D and Table
1). SR are cell-surface glycoproteins that bind modifiedMaleylated BSA (mBSA) is a ligand for numerous scav-
enger receptors (SR) (Abraham et al., 1995). Surprisingly, lipoproteins and a broad spectrum of structurally unre-
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lated ligands such as modified LDL (Ox- and Ac-LDL) waki et al., 1998). Results from FACS analysis using the
anti-LOX-1 mAb 23C11 showed that human peripheral(Dhaliwal and Steinbrecher, 1999), apoptotic cells, and
bacteria-derived cell wall components (i.e., LPS and li- blood myeloid DC and macrophages express LOX-1
(MFI  38  6 and 40  8, respectively; mean  sd,potechoic acid) (Krieger, 1999; Gough and Gordon,
2000). Inhibition assays were then extended to other n  5) (Figure 3A, upper panel). LOX-1 expression is
lower on monocyte-derived immature DC generated byligands of SR. Oxidized-LDL, Ac-LDL, apoliprotein B
(apoB), poly[I], and fucoidan, but not poly[A] (used as culturing monocytes with IL-4 plus GM-CSF (MFI 18
7) and undetectable on T cells and peripheral blooda negative control), also significantly prevented Hsp70
binding to DC, macrophages (Table 1), and monocytes plasmacytoid DC (data not shown). LOX-1 expression
on DC disappears after 2 days’ treatment with the matu-(data not shown). The binding of Hsp60 and Hsp90 to
human DC was also inhibited by mBSA (85  10 and ration factor LPS (data not shown). Western blotting
analysis, performed using the anti-LOX-1 mAb 5-2 (Sa-72  9% inhibition, respectively). These results suggest
that SR could be cell surface binding elements for HSP wamura et al., 1997), confirmed these data (Figure 3B).
As a control, LOX-1 was detected on LOX-1- but noton human APC.
We then analyzed the relative role of CD91 versus SR mock-transfected CHO cells (Figure 3B). In agreement
with these results, LOX-1 mRNA was detected in humanin Hsp70 binding to human macrophages and DC by
evaluating the inhibitory activity of 2M and mBSA (li- monocytes, macrophages, peripheral blood myeloid
DC, B cells, and, as previously reported, in human endo-gands of CD91 and SR, respectively). Maleylated BSA
was more potent than 2M in inhibiting Hsp70 binding thelial cells (Sawamura et al., 1997), but not in T cells
and mature DC (Figure 3C).to peripheral blood myeloid DC (80  10 and 27  5%
inhibition using 2.5 M of the compounds, respectively; The anti-LOX-1 mAb 23C11 but not an isotype control
mAb totally prevented Hsp70 binding to LOX-1-CHO butmean  sd, n  5) (Figure 1D and Table 1). In contrast,
mBSA and 2M inhibited Hsp70 binding to macro- not mock-transfected CHO cells (90  5 and 3  4%
inhibition, respectively; mean  sd, n  5) (data notphages in a similar manner (55  9 and 65  6% inhibi-
tion, respectively) (Figure 1D and Table 1). Transferrin shown). Interestingly, anti-LOX-1 mAb 23C11 also pre-
vented Hsp70 binding to human DC and macrophages(Figure 1D) and BSA (Table 1), used as control proteins,
did not affect Hsp70 binding to DC and macrophages. (45 8% and 329% inhibition, respectively) (Figure 4).
Together, these data show that human immature DCThese results are in agreement with a role for CD91 as
one HSP binding structure on macrophages (Binder et express LOX-1 and evidence LOX-1 as a receptor for
Hsp70 on DC. Whereas inhibition of Hsp70 binding toal., 2000). They also suggest a major role for SR in Hsp70
binding to DC. DC was partial with 23C11, it was total with some SR
ligands (such as mBSA), suggesting that, in addition to
LOX-1, other member(s) of the growing SR family areBinding of Hsp70 to Recombinant LOX-1
expressed on immature DC and bind Hsp70.In order to identify the SR that bind Hsp70, CHO cells
were transfected with cDNA encoding for different SR.
The expression of the recombinant SR by transfected Involvement of LOX-1 in Antigen Cross-Presentation
cells was verified by Western blotting or FACS when HSP mediate peptide re-presentation (Udono and Sri-
appropriate (Figure 2, left panel) as well as by analyzing vastava, 1993; Srivastava et al., 1994; Singh-Jasuja et
the binding of DiI-Ac-LDL (Figure 2, middle panel). Re- al., 2000; Castellino et al., 2000) and also initiate MHC
sults showed that biotinylated Hsp70 bound to LOX-1- class I-dependent immune responses against a whole
transfected CHO cells (LOX-1-CHO) (MFI  875  69; antigen coupled or fused to HSP (Suzue et al., 1997).
mean  sd, n  5) but not to the other SR tested: We thus analyzed whether LOX-1 is involved in Hsp70-
CD36, SR-A1, MARCO, and CLA-1 (Figure 2, right panel). mediated antigen cross-presentation using the murine
Nontransfected CHO cells bind neither Hsp70 nor fluo- ovalbumin (Ova)-specific B3Z CD8 hybridoma cells
rescent Ac-LDL (DiI-Ac-LDL) (data not shown). As con- which produce IL-2 upon stimulation with Ova p257-264
trols, biotinylated TT and BSA do not bind to LOX-1- peptide-Kb complexes (Karttunen et al., 1992). Hsp70
CHO cells (data not shown). LOX-1, initially identified as binds to murine immature DCs (Table 2) and macro-
an Ox-LDL receptor, also binds four-stranded nucleic phages (data not shown), and both cell types express
acids and phospholipids (Sawamura et al., 1997; Mori- LOX-1 (as evidenced by FACS using the 23C11 mAb)
waki et al., 1998). Unlabeled Hsp70, mBSA, and different (Figure 3A, lower panel). The neutralizing 23C11 mAb
ligands of SR (including Ox-LDL, fucoidan, apoB, and but not a control mAb also inhibits Hsp70 binding to
poly[I]) significantly inhibited Hsp70 binding to LOX-1- murine DC and macrophages (45  8 and 29  5%
CHO cells but not the control molecules BSA and poly[A] inhibition, respectively; mean  sd, n  5) (data not
(Table 1). Interestingly, Hsp60 and Hsp90 also bound shown). Murine DC were pulsed with Ova coupled to
to LOX-1-CHO cells (MFI  950  60 and 640  40, Hsp70 (Hsp70-Ova) and exposed to the B3Z T cell hy-
respectively; mean sd, n 5). These data demonstrate bridoma. A 102-fold lower concentration of Ova is re-
that the scavenger receptor LOX-1 is a binding structure quired when coupled to Hsp70 compared with soluble
for Hsp70. Ova alone to induce similar proliferation of the CTLL-2
cell line (Figure 5A). Ova treated with the coupling re-
agent induces similar proliferation to untreated OvaInvolvement of LOX-1 in Hsp70 Binding
to Dendritic Cells (data not shown). Hsp70-Ova-induced IL-2 production
is inhibited by anti-LOX-1 mAb (58 9% inhibition usingThe expression of the protein LOX-1 was reported on
endothelial cells, smooth muscle cells, fibroblasts, and 50 g/ml 23C11) (Figure 5B, left panel). Maleylated BSA
and, to a lower extent, 2M also prevent Hsp70-inducedmonocyte-macrophages (Sawamura et al., 1997; Mori-
Hsp70 Binds to LOX-1
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Figure 3. Hsp70 Binds to LOX-1
(A) Human and murine APCs express LOX-1. Human peripheral blood myeloid and monocyte-derived macrophages (Mφ) and mouse bone
marrow-derived DC and thioglycolate-elicited macrophages were incubated with 10 g/ml Alexa488-labeled anti-LOX-1 mAb 23C11 or isotype
control IgG1 mAb and analyzed by FACS. Gray histogram corresponds to unlabeled cells.
(B) Human APCs express the protein LOX-1. Protein extracts from human monocytes, peripheral blood myeloid DC, monocyte-derived DC
(Mo-derived DC), monocyte-derived macrophages, mature DC (LPS-treated peripheral blood myeloid DC), B cells, and T lymphocytes were
analyzed for LOX-1 expression by Western blotting using the anti-LOX-1 mAb 5-2. Controls were LOX-1- and mock-transfected CHO cells.
(C) APCs express LOX-1 mRNA. The expression of LOX-1 mRNA was analyzed by RT-PCR in human monocytes, macrophages, immature
and mature peripheral blood myeloid DC, B and T lymphocytes, and microvascular endothelial cells (MVEC). The amplified fragments were
size-separated on a 1% agarose gel and visualized by ethidium bromide staining. RNA integrity and cDNA synthesis were verified by amplifying
GAPDH cDNA.
Ova cross-presentation (75 8% and 22 6% inhibition tive immune response against antigen-expressing tumor
cells. We took advantage of the fact that 23C11 recog-using 2 M of the compounds, respectively) (Figure 5B,
right panel). Control IgG1 mAb and transferrin, used as nizes murine LOX-1 (Figure 3A, lower panel). C57BL/6
(H-2b) mice received s.c. injection of 2  104 E.G7 cellsnegative controls, do not modulate Ova cross-presenta-
tion (Figure 5B). These data show that SR, and especially (a C57BL/6 thymoma transfected with Ova cDNA which
is insensitive to NK cell-mediated lysis and to anti-Ova-LOX-1, are involved in in vitro Hsp70-mediated cross-
presentation of a whole antigen. mediated complement-dependent lysis; Storkus et al.,
1989; Zhou et al., 1992) into the right flank and then
injected three times (days 1, 10, and 20) with anti-LOX-1Targeting a Tumor Antigen to LOX-1 In Vivo Elicits
a Protective Immune Response mAb 23C11 coupled to Ova (anti-LOX-1-Ova) plus adju-
vant. Results show that anti-LOX-1-Ova prevents tumorWe therefore evaluated whether targeting a tumor anti-
gen to LOX-1 in vivo could elicit therapeutic and protec- growth in 6/6 mice tested which remained tumor free
after 40 days (Figure 5C). In mice injected with 23C11
alone or 23C11 plus Ova (not coupled), no significant
delay in tumor growth was observed compared to mice
injected with Ova alone (data not shown). In mice in-
jected with isotype control IgG1 coupled to Ova (IgG1-
Ova) plus adjuvant, tumor growth showed a slight delay
compared to mice injected with Ova alone. Lastly, deple-
tion in CD8 T cells prior to injection of anti-LOX-1-Ova
abolished the protective effect of anti-LOX-1-Ova (data
not shown). These results demonstrate that to target in
vivo a tumor Ag to LOX-1 triggers a protective antitumor
immune response.
Discussion
Figure 4. The anti-LOX-1 mAb 23C11 Inhibits Hsp70 Binding to Hu-
The antigen-presenting cells DCs and macrophagesman APCs
play a key role at the interface between innate and adap-Myeloid peripheral blood DC and macrophages were incubated with
tive immunity. They express numerous receptors in-50 g/ml anti-LOX-1 or isotype control mAb prior to addition of 20
nM biotinylated Hsp70 followed by Alexa488-labeled streptavidin. volved in the recognition and endocytosis of a large
Immunity
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Figure 5. LOX-1 Mediates In Vitro and In Vivo
Antigen Cross-Presentation
(A) Ova-Hsp70 is more potent than free Ova
to activate the T cell hybridoma B3Z. Bone
marrow-derived murine DC were pulsed for
8 hr with Ova alone, Ova treated with BS3
(Ova-BS3 ), or Ova coupled to Hsp70 (Ova-
Hsp70) before being washed and recultured
with B3Z T cells. The concentrations of Ova
are indicated in the figure.
(B) Anti-LOX-1 mAb 23C11 prevents in vitro
Hsp70-mediated Ova cross-presentation.
Bone marrow-derived murine DC were
pulsed for 6 hr with Ova-Hsp70 complex (cor-
responding to 10 g/ml Ova) in the absence
or presence of anti-LOX-1 mAb or control
mAb (left panel) or in the presence of mBSA,
2M, or transferrin (right panel), at the indi-
cated concentrations.
(A and B) IL-2 production was evaluated by
measuring the proliferation of the IL-2-depen-
dent cell line CTLL-2. Results are expressed
in cpm (mean  sd, n 3) or as a percentage
of inhibition of CTLL-2 proliferation.
(C) In vivo targeting of LOX-1 induces a pro-
tective antitumoral immune response.
C57BL/6 (H-2b) mice received s.c. injection
of 2  104 E.G7 cells into the right flank fol-
lowed by 40 g of Ova, IgG1-Ova, or anti-
LOX-1-Ova split between both flanks at days
1, 10, and 20. The length (L) and width (W)
was measured at different time points and
tumor volume as L  W2/2.
number of pathogens, such as CD36, CLA-1, and the Previous studies reported that CD91 (2 macroglobu-
lin receptor) is a binding structure for HSP on macro-mannose receptor (Medzhitov and Janeway, 2000).
While macrophages are specialized in ingesting and kill- phages and is involved in HSP-chaperoned peptide re-
presentation (Binder et al., 2000; Basu et al., 2001). Weing as many pathogens as possible, DC are the only
APCs able to prime naive CD4 and CD8 T cells and failed to detect CD91 on human DC, suggesting the
existence of HSP binding structures other than CD91 onto initiate immune responses (Cella et al., 1997; Bancher-
eau et al., 2000). DC. Scavenger receptors bind ligands such as modified
lipoproteins (Abraham et al., 1995), apoptotic cells, andThe process by which some exogenous molecules
(such as HSP, OmpA, and some toxins) (Goletz et al., bacteria-derived cell wall components and maleylated
antigen (Dhaliwal and Steinbrecher, 1999; Krieger,1997; Binder et al., 2000; Jeannin et al., 2000) are endo-
cytosed by APCs via specific receptors, gain access to 1999). We report that mBSA inhibits HSP binding to
DC and macrophages. While mBSA and 2M inhibitedthe MHC class I pathway, and stimulate CD8 cytotoxic
T cells is called cross-presentation. The nature of the Hsp70 binding to macrophages in a similar manner,
mBSA mainly inhibited Hsp70 binding to immature DC.receptors expressed on DC and involved in antigen
cross-presentation remains undetermined. Their identi- In agreement with these results, Basu et al. (2001)
showed that 2M prevents the HSP-mediated peptidefication is of great importance to initiate tumor-specific
cytotoxic responses. We show here that SR, and among re-presentation by the murine macrophage cell line
RAW264.7. Together, these data show that the relativethem LOX-1, are HSP binding structures expressed on
DC and involved in the in vivo generation of protective role of CD91 versus SR in the binding of HSP varies
with the nature of the APC. They also suggest that SRCTL responses.
Hsp70 Binds to LOX-1
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are the main Hsp70 binding structures on DC while both SR in cross-presentation has been previously sug-
CD91 and SR appear involved in Hsp70 binding to mac- gested. Maleylation of an antigen results in both MHC
rophages. Different authors failed to totally inhibit the class I- and class II antigen presentation in vitro (Abra-
binding of labeled Hsp70 to APCs with unlabeled Hsp70 ham et al., 1995; Bansal et al., 1999). In addition, CD36
(Sondermann et al., 2000; Habich et al., 2002; Lipsker is involved in the uptake and cross-presentation of apo-
et al., 2002). This result could be explained by the prop- ptotic bodies by DCs (Albert et al., 1998). Finally, SR-
erties of scavenger receptors. Membrane-bound li- ligand complexes are endocytosed, a mechanism al-
gands are poorly displaced by ligands, a mechanism ready reported for HSP and required for MHC class I
related to the association of SR-ligand complexes with presentation.
microvilli or ruffles. Moreover, SR are rapidly internalized In addition to SR, CD91 has been reported to mediate
following ligand binding and are not subjected to down- antigen cross-presentation by macrophages (Binder et
regulation (Zha et al., 1997). al., 2000; Basu et al., 2001). Pseudomonas exotoxin A
We show that HSP bind to the scavenger receptor (PEA), which targets antigens to the MHC class I path-
LOX-1. LOX-1 was detected on endothelial cells, smooth way (Donnelly et al., 1993), binds to CD91 on macro-
muscle cells, fibroblasts, and monocyte/macrophages phages (Kounnas et al., 1992). Thus, the observation
(Draude et al., 1999). Our results indicate that LOX-1 that the two HSP binding structures identified so far
is also expressed on immature DC. In agreement with (CD91 and LOX-1) are members of two related multili-
Western blotting analysis showing different isoforms of gand lipoprotein receptor families is in agreement with
LOX-1 (probably related to differences in posttransla- the hypothesis that innate cells have evolved to recog-
tional modifications; Kataoka et al., 2000), we report that nize a broad spectrum of danger signals with a restricted
the anti-LOX-1 mAb reveals a broad immunoreactive number of structures (Banchereau et al., 2000; Mat-
band (particularly on DC and macrophages). LOX-1, ini- zinger, 1994; Medzhitov and Janeway, 1997).
tially identified as an Ox-LDL receptor (Asea et al., 2000), We report that targeting tumor antigen to LOX-1 in
also binds four-stranded nucleic acids and phospholip- vivo induces the development of a protective antitumor
ids (Sawamura et al., 1997) and is involved in apoptotic CD8 T cell response. Moreover, mice were resistant
cell phagocytosis via the recognition of phosphatidyl to a second injection of tumor cells, suggesting the
serine (Oka et al., 1998). The observation that com- development of a memory T cell response (data not
pounds that inhibit Ox-LDL binding to LOX-1 totally pre- shown). As previously reported for mycobacteria Hsp70
vent Hsp70 binding to LOX-1-transfected cells suggests (Suzue et al., 1997), Ova has to be covalently coupled
that the binding site(s) of Hsp70 and Ox-LDL on LOX-1 to the anti-LOX-1 mAb to generate a protective anti-
are related or similar. Interestingly, the binding of Hsp70 Ova T cell response. This observation suggests that the
to immature DC was totally inhibited by maleylated anti- anti-LOX-1 mAb acts as a vector to target Ova to the
gen and only partly inhibited by anti-LOX-1 mAb, sug- receptor LOX-1. Injection of IgG1-Ova induced a slight
gesting that other members of the growing SR family delay in tumor growth compared to mice injected with
could be involved in Hsp70 binding to APCs. The identifi- Ova. Previous studies reported that Fc	R mediates anti-
cation of these molecules is under investigation. gen cross-presentation of Ig-antigen complexes in vitro
Previous studies reported the involvement of CD14 (Regnault et al., 1999) and primes antigen-specific CD8
(Asea et al., 2000; Kol et al., 2000), of the complex TLR4/ CTL responses in vivo (Schuurhuis et al., 2002). This
MD2 (Ohashi et al., 2000; Vabulas et al., 2002; Bulut et may contribute to explain why IgG1-Ova initiates a slight
al., 2002), and of TLR2/TLR4 (Asea et al., 2002) in HSP- but significant protective anti-Ova T cell response. In
mediated cell activation. We show that LOX-1 is an vitro and in vivo data show that LOX-1 is one receptor
Hsp70 binding structure expressed on DC. However, we involved in the trafficking of exogenous antigen toward
failed to stimulate APC via LOX-1 (data not shown). the MHC class I pathway. In conclusion, we demonstrate
Whether CD91 is a signaling receptor also remains un-
that the scavenger receptor LOX-1 is expressed on DC
clear (Srivastava, 2002). Together, these data suggest
and is a receptor that triggers the cross-presentation of
that, in response to HSP, both endocytic (LOX-1 and
whole antigens and the initiation of a protective antitu-CD91) and signaling (CD14, TLR2, and TLR-4) receptors
mor immunity. We show that to target scavenger recep-may cooperate to activate APC. This hypothesis is sup-
tors, and especially LOX-1, is a novel approach to initiateported by recent data obtained with yeast (Underhill et
in vivo protective MHC class I-dependent immune re-al., 1999) and OmpA (Jeannin et al., 2000). Additional
sponses.experiments are required to determine the interactions
between endocytic and signaling receptors in HSP-
Experimental Proceduresmediated cell activation.
HSP allow the cross-presentation of chaperoned pep- Cell Isolation
tides and coupled antigens. In order to analyze the role Cells were cultured in RPMI 1640 medium supplemented with 10%
of LOX-1 in this pathway, we used ovalbumin coupled FCS, 2 mM L-glutamine, and antibiotics (cRPMI) (all from Life tech-
to Hsp70 (Suzue et al., 1997) to activate the T cell hybrid- nologies, Cergy Pontoise, France). Human BDCA-1 (CD1c),
CD11chigh, and CD123low blood myeloid dendritic cells (Dzionek etoma B3Z, a model in which elicitation of CD8 T cells
al., 2000) were isolated using magnetic beads following instructionsby a fusion protein is not dependent on the chaperone
(Miltenyi Biotech, Bergish Gladbach, Germany). Human monocytesproperties of the HSP (Huang et al., 2000). We show
were isolated from peripheral blood mononuclear cells (PBMC) with
that LOX-1 is involved in the MHC class I-dependent anti-CD14 mAb-coated magnetic beads (Miltenyi Biotech). Macro-
presentation of Hsp70-associated Ag. Thus, in addition phages were generated by culturing monocytes for 5 days in cRPMI
to having a role in lipid metabolism, SR may play a major containing 2 ng/ml GM-CSF plus 20 ng/ml M-CSF (R&D Systems,
Abingdon, UK). Immature monocyte-derived dendritic cells wererole in antigen cross-presentation. The involvement of
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generated by culturing monocytes with 20 ng/ml IL-4 plus 20 ng/ml cells used as control, the 23C11 clone was expanded and used for
ascites fluid production. The 23C11 mAb was purified using proteinGM-CSF (R&D Systems). In some experiments, human monocyte-
derived DC and peripheral blood myeloid DC were treated with 10 A/G column (Pierce). The 23C11 mAb was used for FACS analysis
and neutralizing experiments.ng/ml LPS (from Escherichia coli isotype O111:B4; Sigma, St. Louis,
MO) for 2 days to induce DC maturation. All the experiments using
human DC were performed with freshly isolated CD11c myeloid Binding Experiments
peripheral blood DC, except Western blotting analysis that also Biotinylated Hsp70 was incubated at 4C for 30 min in FACS buffer
presented LOX-1 expression in monocyte-derived DC. T cells were (PBS containing 0.1% BSA and 0.05% NaN3) and then washed in
purified from peripheral blood mononuclear cells (PBMC) by ros- FACS buffer. Cells were then incubated with FITC-labeled streptavi-
eting with sheep red blood cells, and B cells were purified by FACS- din (Molecular Probes, Eugene, OR) for 20 min at 4C before wash-
sorting the CD19 cells. Myeloid mouse immature DC were gener- ings with FACS buffer. Fluorescence was analyzed using a FACScan
ated by culturing bone marrow cells from C57BL/6 (H-2b) mice (Iffa (BD Biosciences, Franklin Lakes, NJ). In some experiments, cells
Credo, L’Arbresle, France) for 6 days with 3 ng/ml murine GM-CSF were preincubated with unlabeled Hsp70, Hsp90, BSA, maleylated
(R&D Systems). BSA (mBSA), polyinosinic acid (poly[I]), polyadenosic acid (poly[A])
(all from Sigma), Ox-LDL, or Ac-LDL (both from Biogenesis, Poole,
UK) for 20 min at 4C before incubation with biotinylated Hsp70.Proteins
Bound Hsp70 was detected as described above.Recombinant Hsp70 (StressGen Biotechnologies Corp, Victoria BC,
Canada) and TT (SBL vaccine, Stockholm) were biotinylated using
a commercial kit (Pierce, Rockford, IL). In order to remove contami- Analysis of LOX-1 mRNA Expression by RT-PCR
nating endotoxin, biotinylated Hsp70 was passed through a column The expression of the mRNA encoding for LOX-1 in professional
containing polymixin B coupled to resin (Pierce). The endotoxin APCs compared with microvascular endothelial cells (MVEC) was
level, determined by the limulus assay (Chromogenix, Milano, Italy), evaluated by RT-PCR. In brief, cells were resuspended in 1 ml Trizol
was less than 0.5 EU/mg biotinylated Hsp70. The cDNA sequences reagent (Life Technologies). After extraction with chloroform, total
corresponding to the extracellular domain 71-273 of human LOX-1 RNA was precipitated with isopropyl alcohol. Single-strand cDNA
was inserted in the expression vector Signal pIg-Tail (R&D Systems) was synthesized using 2 g of total RNA by reverse transcription
in frame with the murine Fc	1 (LOX-1-muFc). The fusion proteins using an oligo-dT primer and reverse transcriptase (Promega, Madi-
were produced in PEAK cells (EdgeBio systems, Gaithersburg, MD) son, WI). PCR amplification was performed with an amount of cDNA
cultured in Optimem medium (Life technologies), and purified using corresponding to 25 ng of starting total RNA (2 min at 94C followed
protein A immobilized on agarose (Pierce). by 30 cycles (30 s at 94C, 1 min at 60C, and 1 min at 72C) followed
by a final extension of 4 min at 72C) using specific oligonucleotides
(5
-ACTGGAGGGACAGATCTCAGCCGG-3
 and 5
-GGAAATTGCTTransfectants
TGCTGGATGAATCC-3
). RNA integrity was assessed by GAPDHThe cDNA encoding for CD14 and the scavenger receptors CD36,
cDNA amplification. The PCR products were analyzed on a 1%MARCO, SR-AI, LOX-1, and CLA-1 were subcloned in the expression
agarose gel by electrophoresis in the presence of ethidium bromide.vector pEBS/PL containing a sequence encoding the protein C tag
(EDQVDPRLIDGK) in frame with the inserted sequence. CHO cells
Analysis of LOX-1 Expression by Human APCs(ATCC, Manassas, VA) were transfected using Fugene-6 (Roche
The expression of LOX-1 in monocytes, immature DC, macro-Diagnostic, Meylan, France) and cultured in ISCOVE medium sup-
phages, B cells, and T lymphocytes was evaluated by FACS andplemented with 10% FCS and selected with hygromycin (all from
Western blotting. Controls included LOX-1-CHO cells and nontrans-Life Technologies) before clones were picked. Transfectants were
fected cells. LOX-1 expression was analyzed by FACS usingselected as followed: CD14- and CD36-expressing cells were sorted
Alexa488-labeled anti-LOX-1 23C11 mAb. Results are expressed inby FACS using FITC-labeled anti-CD14 and anti-CD36 mAb (BD
MFI after subtraction of the MFI obtained with the control mAb. ForPharmingen, San Diego, CA), respectively; LOX-1-expressing cells
Western blotting, after cell lysis, proteins were separated by SDS-were isolated by FACS sorting using the anti-LOX-1 mAb 23C11
PAGE in a 10%–20% polyacrylamide gradient gel and transferred(see above); MARCO-, CLA-1-, and SR-AI-expressing cells were
to a PVDF membrane. The membrane was probed with the anti-isolated by FACS sorting using fluorescent DiI-Ac-LDL (Harbor Bio-
LOX-1 antibodies #5-2 (Sawamura et al.,1997). Bound Abs wereproducts, Strougthon, MA). The expression of the SR was verified
visualized using the avidin-biotin system (Vector, Burlingame, CA)by FACS or by Western blotting when appropriate. CD14, CD36,
and Konica Immunostaining kit (Konica, Mahwah, NJ).and LOX-1 expression was analyzed by FACS using specific mAbs.
MARCO expression was analized by FACS using anti-tag protein
detected with FITC-labeled anti-mouse Ig mAb (Silenus, Melbourne, Activation of the Ova-Specific T Cell Hybridoma B3Z
Australia). Isotype control mAbs were from BD Pharmingen. Results B3Z T cell hybridoma cells are specifically activated by the Ova-
are expressed in MFI after subtraction of the MFI obtained with the derived peptide SIINFEKL presented by H-2Kb. Ovalbumin (Ova)
isotype control mAb. SR-A1 and CLA-I expression was evaluated (Worthington, Lakewood, NJ) was coupled to Hsp70 (Ova-Hsp70)
by Western blotting. In brief, cells were lysed in 10 mM phosphate using bis(sulfosuccinimidyl)suberate (BS3 ) used at 0.25 mM as de-
buffer (pH 7.4) containing 0.5% Nonidet P40 (Sigma) and protease scribed by the manufacturer (Pierce). As a control, Ova was treated
inhibitors (Boehringer Mannheim, Mannheim, Germany). Proteins with BS3 (Ova-BS3 ). Proteins and conjugates were assayed with the
from 5  106 cells were electrophoretically separated on a 10% BCA kit (Pierce). The quantity of coupled Ova was determined by
polyacrylamide gel in nonreducing conditions and then transferred ELISA using specific anti-Ova Abs. Immature DC/macrophage pre-
to a nitrocellulose membrane (Biorad, Ivry sur Seine, France). After cursors were generated as previously reported and pulsed for 8 hr
saturation, membranes were incubated with an anti-protein C mAb in FCS free medium with Hsp70, Ova alone, Ova-BS3, or Ova-Hsp70.
(Roche Diagnostics). After washing, membranes were incubated After washings, 5  105 pulsed DC were cultured with 5  105 B3Z
with peroxydase-labeled anti-mouse IgG Ab (Dako, Glostrup, Den- cells. In some experiments, DC were incubated with Ova-Hsp70 in
mark) and bound Abs were detected using the ECL system (Amer- the presence of a 2M, mBSA, transferrin, anti-LOX-1 mAb 23C11,
sham Biosciences, Uppsala, Sweden). or control mAb. IL-2 production in the 16 hr supernatants was evalu-
ated by measuring the proliferation of the IL-2-dependent cell line
CTLL-2 (ATCC).Generation of an Anti-Human LOX-1 mAb
The anti-LOX-1 mAb 23C11 was produced by immunizing BALB/c
mice (Iffa Credo) intraperitoneally with 100 g of LOX-1-muFc in Treatment of Established Tumors
Groups of six mice received s.c. injections of 1.5  104 E.G7 cellscomplete Freund’s adjuvant. A second immunization was performed
with incomplete Freund’s adjuvant. Four days after a further intrave- ATCC) into the right flank followed by 100 g of Ova, Ova coupled
to anti-LOX-1 mAb 23C11 (anti-LOX-1-Ova) or to a control mAbnous inoculation of 50 g/ml LOX-1-muFc, mice were killed and
spleen cells were fused with SP2/O-Ag14 myeloma cells. After (IgG1-Ova) (Sigma) split between both flanks with incomplete
Freund’s adjuvant at days 1, 10, and 18. The tumor length (L) andscreening by FACS using LOX-1-CHO cells and nontransfected CHO
Hsp70 Binds to LOX-1
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width (W) was measured at different time points, and tumor volume tion and antigen presenting function of dendritic cells. Curr. Opin.
Immunol. 9, 10–16.was determined by L  W2/2.
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